Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naga Chalasani

Showing results (1-10 of 453) with videos related to

Pageof 46
Sort By:
Gastroenterology & Hepatology|August 29, 2024
Current Status of Genetics and Polygenic Risk Scores in Metabolic Dysfunction-Associated SteatohepatitisNaga Chalasani
Hepatology (Baltimore, Md.)|February 15, 2018
ReplyNaga Chalasani,
Gastroenterology|July 30, 2009
Nonalcoholic fatty liver disease liver fat score and fat equation to predict and quantitate hepatic steatosis: promising but not prime time!Naga Chalasani
Hepatology (Baltimore, Md.)|January 9, 2013
Reply: To PMID 22488764Naga Chalasani, , , et al.
Hepatology (Baltimore, Md.)|March 25, 2005
Statins and hepatotoxicity: focus on patients with fatty liverNaga Chalasani
Gastroenterology|October 9, 2007
Noninvasive markers of advanced histology in nonalcoholic fatty liver disease: are we there yet?Spencer Wilson, Naga Chalasani
The American Journal of the Medical Sciences|March 16, 2005
Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III)Suthat Liangpunsakul, Naga Chalasani
Hepatology (Baltimore, Md.)|December 10, 2008
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and managementRaj Vuppalanchi, Naga Chalasani
The American Journal of Pathology|May 22, 2010
Challenging the rodent hegemony: a new rabbit model of nonalcoholic steatohepatitisJaideep Behari, Naga Chalasani
Clinical Liver Disease|April 18, 2019
Causality Assessment for Suspected Drug-Induced Liver Injury in Patients With Underlying Chronic Liver DiseaseLara Dakhoul, Naga Chalasani
Pageof 46

Showing results (1-10 of 453) with videos related to

Sort By:
Pageof 46
Gastroenterology & Hepatology|August 29, 2024
Current Status of Genetics and Polygenic Risk Scores in Metabolic Dysfunction-Associated SteatohepatitisNaga Chalasani
Hepatology (Baltimore, Md.)|February 15, 2018
ReplyNaga Chalasani,
Gastroenterology|July 30, 2009
Nonalcoholic fatty liver disease liver fat score and fat equation to predict and quantitate hepatic steatosis: promising but not prime time!Naga Chalasani
Hepatology (Baltimore, Md.)|January 9, 2013
Reply: To PMID 22488764Naga Chalasani, , , et al.
Hepatology (Baltimore, Md.)|March 25, 2005
Statins and hepatotoxicity: focus on patients with fatty liverNaga Chalasani
Gastroenterology|October 9, 2007
Noninvasive markers of advanced histology in nonalcoholic fatty liver disease: are we there yet?Spencer Wilson, Naga Chalasani
The American Journal of the Medical Sciences|March 16, 2005
Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III)Suthat Liangpunsakul, Naga Chalasani
Hepatology (Baltimore, Md.)|December 10, 2008
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and managementRaj Vuppalanchi, Naga Chalasani
The American Journal of Pathology|May 22, 2010
Challenging the rodent hegemony: a new rabbit model of nonalcoholic steatohepatitisJaideep Behari, Naga Chalasani
Clinical Liver Disease|April 18, 2019
Causality Assessment for Suspected Drug-Induced Liver Injury in Patients With Underlying Chronic Liver DiseaseLara Dakhoul, Naga Chalasani
Pageof 46